Effect of Lucinactant on Mucus Clearance in Cystic Fibrosis Lung Disease

• Status: Completed
• Trial end date: 2010-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Mucus clearance is impaired in cystic fibrosis. Inhaled surfactants may reduce adhesive forces between mucus and airway surfaces and improve mucus clearance. This in turn my improve lung health. The investigators propose to measure mucus clearance before and after lucinactant or vehicle administration in patients with cystic fibrosis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of North Carolina, Chapel Hill
• Collaborators: Cystic Fibrosis Foundation; Cystic Fibrosis Foundation Therapeutics; Windtree Therapeutics
• Treatments: Pulmonary Surfactants

Criteria

Inclusion Criteria:

• Cystic fibrosis

• FEV1>40%

Exclusion Criteria:

• Unstable lung disease

• Unable or unwilling to stop hypertonic saline and dornase alfa for 3 days prior to each study period

• Relevant drug allergy or intolerance

• Recent investigational drug use (30 days)